Observational studyJournal of gastrointestinal cancer2026
Retrospective Analysis of Diagnostic and Prognostic Value of Serum Glypican-3 in Patients With HCV-Related Cirrhosis With Or Without HCC After Achieving SVR With DAA Treatment.
Observational study in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDespite achieving sustained virologic response (SVR) after treatment with direct-acting antivirals (DAAs), patients with hepatitis C virus (HCV)-related cirrhosis remain at risk of hepatocellular carcinoma (HCC) development. Glypican-3 (GPC-3) is a heparan sulfate proteoglycan with oncogenic role in HCC. This study aimed to assess the diagnostic and prognostic value of serum GPC-3 in patients with HCV-related cirrhosis who achieved SVR following DAA therapy.
methodsWe conducted a retrospective, observational study including 832 patients with HCV-related cirrhosis treated with DAAs between 2014 and 2024. Patients were divided into two cohorts: cohort A (n = 551) without HCC at enrolment and cohort B (n = 281) with established HCC. Serum GPC-3 was measured using a commercially available enzyme immunoassay (CanAg Glypican-3 EIA, Fujirebio Diagnostics AB, Gothenburg, Sweden).
resultsWe analyzed 832 single serum samples: collected at SVR12 in Cohort A and at HCC diagnosis in Cohort B. GPC-3 levels were significantly higher in patients with HCC compared to those without (95, 50-185 pg/mL vs. 48, 29-79 pg/mL; p < 0.001), with moderate diagnostic accuracy (AUC = 0.711). During follow-up (37, 20-51 months), GPC-3 levels did not predict the development of de novo HCC in cohort A. However, in cohort B, GPC-3 > 150 pg/mL was independently associated with reduced survival (adjusted HR = 1.68, 95% CI 1.03-2.67, p = 0.036).
conclusionsWhile GPC-3 may be of limited utility for predicting HCC occurrence in patients cured of HCV, it could represent a valuable prognostic factor able to predict survival of patients with established HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.